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mihail.zilbermint@nih.govSummaryAutosomal recessive pseudohypoaldosteronism type 1 (PHA1) is a rare disorder characterized by sodium wasting, failure to
thrive, hyperkalemia, hypovolemia and metabolic acidosis. It is due to mutations in the amiloride-sensitive epithelial sodium
channel (ENaC) and is characterized by diminished response to aldosterone. Patients may present with life-threatening
hyperkalemia, which must be recognized and appropriately treated. A 32-year-old female was referred to the National
Institutes of Health (NIH) for evaluation of hyperkalemia and muscle pain. Her condition started in the second week of life,
when she was brought to an outside hospital lethargic and unresponsive. At that time, she was hypovolemic, hyperkalemic
and acidotic, and was eventually treated with sodium bicarbonate and potassium chelation. At the time of the presentation
to the NIH, her laboratory evaluation revealed serum potassium 5.1 mmol/l (reference range: 3.4–5.1 mmol/l), aldosterone
2800 ng/dl (reference range: %21 ng/dl) and plasma renin activity 90 ng/ml/h (reference range: 0.6–4.3 ng/ml per h).
Diagnosis of PHA1 was suspected. Sequencing of the SCNN1B gene, which codes for ENaC, revealed that the patient is a
compound heterozygote for two novel variants (c.1288delC and c.1466C1 GOA), confirming the suspected diagnosis of
PHA1. In conclusion, we report a patient with novel variants of the SCNN1B gene causing PHA1 with persistent, symptomatic
hyperkalemia.Learning points:
† PHA1 is a rare genetic condition, causing functional abnormalities of the amiloride-sensitive ENaC.
† PHA1 was caused by previously unreported SCNN1B gene mutations (c.1288delC and c.1466C1 GOA).
† Early recognition of this condition and adherence to symptomatic therapy is important, as the electrolyte
abnormalities found may lead to severe dehydration, cardiac arrhythmias and even death.
† High doses of sodium polystyrene sulfonate, sodium chloride and sodium bicarbonate are required for symptomatic
treatment.http://www.edmcasereports.com
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Pseudohypoaldosteronism type 1 (PHA1) is a rare genetic
condition affecting one in 80 000 births (1). It was first
described by Cheek & Perry (2). In affected patients,
aldosterone levels are adequate or elevated, but the renal
response to aldosterone is disrupted due to functional
abnormalities in either the mineralocorticoid receptor
(autosomal dominant or sporadic PHA1) or the amiloride-
sensitive epithelial sodium channel (ENaC) (autosomal
recessive PHA1) (Fig. 1).
The ENaC channel is present in all aldosterone-
responsive target organs including kidney, colon, lung
and sweat glands. Autosomal recessive PHA1 is associated
with permanent resistance to aldosterone in these organs
and is clinically characterized by severe sodium wasting,
hypovolemia, hyperkalemia, metabolic acidosis and fail-
ure to thrive (3, 4). Affected patients may also experience
recurrent pulmonary infections in a pattern that is
indistinguishable from cystic fibrosis (5).
The ENaC is a trimer composed of three homologous
subunits, such as a-, b- and g-ENaC (6, 7). Aldosterone
resistance may result from mutations in any of these
subunit genes: alpha (SCNN1A; 12p13), beta (SCNN1B;
16p12.2–p12.1) or gamma (SCNN1G; 16p12). As an
autosomal recessive disease, both alleles of each gene
must be abnormal for this form of PHA1 to occur. Here we
present a case of a patient with severe hyperkalemia due to
PHA1 resulting from compound heterozygosity for two
SCNN1B mutations.PRINCIPAL CELL
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Figure 1
Mechanism of the epithelial sodium channel and disruption by PHA type 1
in the distal nephron. ENaC, epithelial sodium channel; Aldo., aldosterone;
AR PHA Type 1, autosomal recessive pseudohypoaldosteronism type 1.
http://www.edmcasereports.comCase presentation
A 32-year-old African American female was referred to the
National Institutes of Health (NIH) Clinical Center with
the chief complaint of hyperkalemia and muscle aches.
At 2–3 weeks of age, the patient was found to have
multi-organ dysfunction when she was brought to a
children’s hospital lethargic and unresponsive. At that
time, she was found to be hyperkalemic, hypovolemic and
acidotic. She was hospitalized multiple times until 2 years
of age and maintained on sodium chloride repletion,
sodium bicarbonate, potassium chelation and a diet of
high salt and limited potassium. She was also prescribed
fludrocortisone with no clinical response. After hospital-
ization, she received sodium chloride, sodium bicarbonate
and potassium chelation via gastrostomy tube until being
transitioned to the respective oral medications at 3.5 years
of age. The patient also reported recurrent episodes of
chronic bronchitis during childhood.
She was clinically stable until age 32 years, when she
began to experience severe body aches, with pain limiting
her motion and no relief to multiple analgesic medi-
cations. She also noted heart palpitations and frequent
episodes of hidradenitis suppurativa. In September 2012,
she was admitted to an outside hospital and found to have
a serum potassium level of 6.6 mmol/l (reference range:
3.5–5.1 mmol/l) and heart rate of 150 beats/min. Hyper-
kalemia was treated with fluid repletion and sodium
polystyrene sulfonate, and she was referred to our clinic.
The patient’s presentation at this age was postulated to be
due to medication non-adherence.Past medical and surgical history
The patient’s past medical history included obesity and a
history of pulmonary embolism with secondary pulmon-
ary hypertension. She underwent pulmonary endarter-
ectomy at age 29 years, with subsequent resolution of her
pulmonary hypertension. Family history included amyo-
trophic lateral sclerosis in her father and was negative for
other medical conditions including PHA.Investigation
Evaluation at the NIH
On presentation to the NIH, she complained of diffuse
muscle aches and increased thirst. Physical exam was
notable for blood pressure of 128/75 mmHg, heart rate
110 beats/min, BMI 41.4 kg/m2 and mild acanthosis2
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evaluation are shown in Table 1. Computed tomography
scan of the adrenal glands (Fig. 2) showed normal right
adrenal gland with no hyperplasia and left adrenal gland
with two nodules 1.8!1.5 cm and 1.6!1.1 cm.Figure 2
Computed tomography of adrenal glands. Normal right adrenal gland with
no hyperplasia and left adrenal gland with two nodules 1.8!1.5 cm and
1.6!1.1 cm.Genetic analysis
Genetic analysis (performed by GeneDx, Gaithersburg,
MD, USA) revealed the presence of two novel hetero-
zygous mutations in the SCNN1B gene (OMIM: 600760;
NM_000336.2): c.1288delC, a one-base deletion that
generates a frameshift mutation, and c.1466C1 GOA, an
intronic base substitution that leads to a splice site
mutation. These variants have not been published in the
literature or listed in public domain (http://www.ncbi.
nlm.nih.gov/variation/tools/1000genomes/ and http://
exac.broadinstitute.org). Based on these findings, a diag-
nosis of PHA1 was confirmed. Other candidate genes
SCNN1A and SCNN1G were sequenced as well, but no
mutations were found.Table 1 Laboratory evaluation at the National Institutes of
Health.
Laboratory testa Value
Reference
range
Initial presentation
Sodium (mmol/l) 135 136–145
Potassium (mmol/l) 5.1 3.4–5.1
24-h urine sodium (mmol/l) 110 40–220
Bicarbonate (mmol/l) 20 22–29
Plasma renin activity (ng/ml per h) 190 !0.6–4.3b
Aldosterone (ng/dl) 2800 !21
Hemoglobin-A1c (%) 5.8 !6.5
Subsequent evaluation
Adrenocorticotropic hormone
(pg/ml)
9.6 0.0–46.0
Compound S (ng/dl) 13.7 0.0–49.9
Insulin-like growth factor 1 (ng/ml) 76 115–307
Dehydroepiandrosterone (ng/dl) 155 0–599
Dehydroepiandrosterone sulfate
(mcg/ml)
0.98 0.35–4.30
Androstenedione (ng/dl) 93 17–175
17-OH Progesterone (ng/dl) 49 3–175
Total testosterone (ng/dl) !20.0 !81
Enhanced estradiol (pg/ml) 242.7 12–460
Progesterone (ng/ml) 1.1 0.2–1.5
Follicle stimulating hormone (U/l) 4.1 3–11
Luteinizing hormone (U/l) 5.3 1–12
Prolactin (mcg/l) 17.4 2.0–25.0
Sex hormone binding globulin
(nmol/l)
75 18–114
All laboratory tests in serum.
aIn serum, except where indicated.
bIn sodium-replete individuals.
http://www.edmcasereports.comIn silico analysis was performed in order to better
understand the possible protein defects generated by those
two mutations. Two different software programs were
used: mutation taster (http://www.mutationtaster.org)
and Human Splicing Finder (http://www.umd.be/HSF3/
HSF.html). The mutation c.1288delC/p.L430Yfs*3 gener-
ated a frameshift mutation probably leading to the loss
of the domains: TOPO_DOM Extracellular (amino acids
76–514), TRANSMEM Helical (amino acids 515–545) and
TOPO_DOM Cytoplasmic (amino acids 546–640). The
mutation c.1466C1GOA probably leads to a splice site
donor lost. The predicted new protein, if intron 11 is
maintained, is p.R489Rfs*42. If the splice site donor is lost,
the domains thatmight get lost are the same present in the
mutation c.1288delC.Treatment
She was treated with sodium polystyrene sulfonate
60 ml/day, sodium chloride 3 G/day and sodium
bicarbonate 950 mg/day, which normalized her serum
potassium levels, but she continued with diffuse muscle
aches.Outcome and follow-up
With maintenance sodium polystyrene sulfonate
(60 ml/day), sodium chloride (3 G/day) and sodium
bicarbonate (950 mg/day) therapy, the patient’s electro-
lyte levels including sodium, potassium and bicarbonate
have remained within normal limits. At her most recent
evaluation, the patient had been on therapy for
2 years since her initial adult outpatient evaluation at
the NIH. Electrolyte levels including sodium, potassium3
1 2 3 4 5 6 7 8 9 10 11 12 13 14
c.1288deIC c.1466+1G>A
Figure 3
Schematic representation of the SCCN1B gene showing the localization of
the two mutations found in the patient. Blue boxes represent the coding
exons and green boxes represent the 5 0 and 3 0 untranslated region (UTR);
dotted line represents the intron region.
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renin activity and serum aldosterone level remained
elevated to 270 ng/ml per h (reference range: %0.6–4.3)
and 3500 ng/dl (reference range: %26.0) respectively.
The patient was tolerating the treatment well. She was
counseled regarding the adherence to the treatment
regimen, which is crucial in her condition.Discussion
Wepresent a case of a patient with two novel heterozygous
SCNN1B mutations resulting in severe hyperkalemia due
to PHA1. Though several cases of patients with PHA1 have
previously been presented, the majority of reported
mutations are in the subunit of a-ENaC, with mutations
in b- and g-ENaC only rarely described. We speculate that
the variants identified are pathogenic because the patient
presented with the PHA1 phenotype and the mutations
are identified in a gene known to cause PHA1. We also
performed an in silico analysis that predicted that both
mutations are probably pathogenic. The structure of
SCNN1B is shown in Fig. 3. Additional reports of
SCNN1B and SCNN1G mutations will help to deepen
understanding of different ENaC subunits’ structure,
function and contribution to disease in PHA1.
In response to aldosterone, the ENaC channel is the
key mediator of sodium reabsorption from the renal
cortical collecting tubule (8). Coupled with the basolateral
sodium–potassium ATPase, ENaC acts both directly to
reabsorb sodium and indirectly to facilitate potassium
secretion (3). As a result, mutations in this channel most
commonly produce the clinical picture of failure to thrive,
hypovolemia due to sodium wasting, metabolic acidosis
and severe hyperkalemia (3, 4), as seen in our patient.
Although fortunately not present in our patient, severe
hyperkalemia may manifest with a range of clinical signs,
from weakness or flaccid paralysis (9) to severe arrhyth-
mias (10). PHA1 due to mutations in ENaC affects a rangehttp://www.edmcasereports.comof organ systems; patients may also present with skin and
pulmonary infections or severe diarrhea (11). PHA1 due to
mutation in the NR3C2 gene, encoding the mineralocor-
ticoid receptor, is a milder disease affecting only the
kidneys, with symptoms generally resolving in infancy
(12). In patients suspected of having PHA1 based on these
clinical signs and laboratory findings, the diagnosis is
formally made through genetic testing to identify
mutations in NR3C2, SCNN1A, SCNN1B or SCNN1G.
A limitation of our study is that the patient’s parents’
genetic informationwasnotobtained. Basedon thecurrent
understanding of PHA1, we speculate that mutations in
the ENaC-coding genes all contribute to autosomal
recessive disease, while mutations in mineralocorticoid
receptor-coding genes contribute to autosomal-dominant
disease. However, without parents’ genetic information,
we cannot confirm that the mutations identified are
autosomal recessive rather than de novo mutations.
Future studies should consider assessing genetic infor-
mation of both patients with PHA1 and their parents in
order to better understand the transmission of novel
mutations.
Management of patients with PHA1 strives to replace
sodium chloride, bicarbonate and fluid, and promote
excretion of potassium through administration of high
doses of sodium polystyrene sulfonate. In patients with
refractory salt wasting, indomethacin may be adminis-
tered in order to reduce urinary sodium losses through its
inhibition of prostaglandin synthesis (13, 14).Declaration of interest
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